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HIV infection, togetherwithART, is associatedwith changes in biochemical,metabolic parameters and lipid profiles.The aimof this
studywas to compare changes in lipid profiles amongHIVpositive outpatients over ninemonths. 171 patients were investigated, 79%
were ART experienced, and 82% of ART experienced patients were on NVP/EFV first line at baseline, but some patients changed
ART groups over follow-up and classification was based on intent to treat.More than 60%ARTnaı¨ve andART experienced patients
had some formof dyslipidemia either at baseline or at follow-up, butmean lipid values for the two groupswere within normal limits.
At baseline and follow-up, mean levels of TC and HDL were slightly higher in the ART experienced group. Interestingly, there was
higher increase inHDL over time in the ART negative group compared to the ART positive group.There was a decrease in TC/HDL
ratio in both groups over time, suggesting a reduction in calculated risk of CHD over time. HIV positive patients frequently show
various forms of dyslipidemia, but there are no changes in average atherogenic lipid levels and results suggest reduced risk of CHD,
mainly due to increases in HDL, after nine months of observation time.
1. Introduction
To date, HIV remains a major public health threat in Africa
as a whole and in Zimbabwe alone where prevalence of
HIV-infected adults is 14.4% [1, 2]. Though HIV infection
and antiretroviral therapy (ART) are often associated with
a variety of changes in biochemical and metabolic param-
eters including changes in lipid profiles, ART regimens
have revolutionized the care and management of acquired
immune deficiency syndrome (AIDS) due to HIV and have
transformed the disease from a life-threatening infection into
a chronic and manageable condition [1, 3].
Whilst ART does not cure AIDS and is therefore taken
for life, it reduces morbidity and mortality, if used appro-
priately [1, 3]. The national ART program in Zimbabwe
began in April 2004, and since that time the benefits of such
therapy have been widely documented in the country [4].
Current World Health Organization and 2013 antiretrovi-
ral guidelines for Zimbabwe recommend a preferred first-
line regimen for adults, adolescents, and older children of
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two nucleotide/nucleoside reverse transcriptase inhibitors
(NRTIs), for example, tenofovir (TDF) and lamivudine (3TC)
togetherwith nonnucleotide/nucleoside reverse transcriptase
inhibitor (NNRTI), for example, efavirenz (EFV) and nevi-
rapine (NVP) and a second-line ART regimen of boosted
protease inhibitor (PI) supported by NRTIs [4–6].
Infection with HIV impairs the reverse cholesterol
transport (RCT) process in macrophages and monocytes;
hence clinical observations have documented dyslipidemia
in patients with AIDS and symptomatic HIV infection. The
earliest alterations recognized, in terms of disease stage,
are decreases in high density lipoprotein (HDL) and low
density lipoprotein (LDL) concentrations [7]. Further clinical
observations, results of clinical trials, and results of studies in
healthy adult volunteers have documented metabolic effects
on lipid metabolism by NRTIs, NNRTIs, and PIs [8, 9].
NRTIs are associated with alterations in body fat deposition
and metabolic alterations, due to drug accumulation within
adipocytes resulting in mitochondrial dysfunction [10]. On
the other hand, NNRTIs such as efavirenz (EFV) and nevi-
rapine (NVP) [9, 11] have been associated with favourable
lipid profiles. In particular, ART regimens containing NVP
are associated with a better lipid profile, mainly because they
provide higher serum concentrations of HDL [12]. Patients
who use PIs for a long period of time, however, frequently
presentwith hypertriglyceridemia, elevated concentrations of
LDL, and reduced HDL levels, all of which are atherogenic
changes [13–15].
In the 987 Home Based Aids Care Program [16] a study
of 374 patients was carried out in Uganda; mean serum lipid
concentrations of TC, LDL, and HDL increased after 24
months of NVP/EFV treatment, in agreement with an Indian
study showing an increase in TC and TG levels after 20
months on NVP/EFV regimens. Furthermore, a multicenter
study fromMadrid showed an increase in TC after 12-month
treatment with PI-based drug regimen comprising lopinavir
and ritonavir (LPV/RTV) [16–18].
Clinicians offering health care to HIV positive patients
need to be aware of the various clinical and biochemical
presentations and hence to keep a high level of suspicion.
Due to the presence of contradicting study results, it is not
clear where the Zimbabwean population stands with regard
to changes in lipid profiles in patients on different ART
regimens, over time. In the current era of HIV infection
and ART, knowing patients’ risk and acting to reduce it are
imperative to long-term survival.The aim of this longitudinal
study was to determine and to compare the changes in
lipid profiles in ART experienced and ART na¨ıve patients
previously described at baseline [19] after nine months of
follow-up.
2. Materials and Methods
2.1. Study Design, Study Site, and Recruitment. This was a
cohort prospective observational study. Documented HIV-
infected patients aged 18 years and above who attended
the HIV treatment clinic in Harare between March and
August 2013 were consecutively recruited into the study after
giving informed consent [19] and followed up nine months
later. Demographic and clinical data were as follows: age,
sex, marital status, health status, clinical history, and family
history were collected at baseline [19]. Blood samples in
plain tubes were collected at baseline and nine months later,
separated and stored at −80∘C, and then thawed once before
analysis.
2.2. Ethical Considerations. Ethical clearance to carry out the
study was granted by the Joint Research Ethics Committee of
the University of Zimbabwe College of Health Sciences and
Parirenyatwa Group of Hospitals (JREC) (173/11), Medical
Research Council of Zimbabwe (MRCZ) (MRCZ/B/352), and
Norwegian Research Ethics Committee (REK) (20121100).
Permission to access patient samples and data was granted
by the clinic research committee after they were satisfied that
the research protocol would not interfere with the usual clinic
practice.
2.3. QuantitativeDetermination of Lipids. TC,HDL, andLDL
were measured enzymatically in serum in a series of coupled
reactions as described earlier [19].
2.4. Statistical Analysis. Stata® version 13 (StataCorp, Texas)
was used to analyse the data. A 𝑃 value < 0.05 was considered
as statistically significant. Baseline continuous, normally
distributed variables were compared between the two inde-
pendent groups using 𝑡-tests, and categorical variables were
compared using Pearson’s chi square tests while binominal
results at the two time points were compared by McNe-
mar’s chi square tests using the exact binomial probabilities.
Generalised linear models for the change in outcome values
over time were constructed for each lipid (cholesterol, HDL,
LDL, and TC/HDL ratio) whilst independent variables tested
included ART history, sex, age, and BMI at baseline. The
models used robust standard errors to adjust for the clus-
tering in repeated measures of patients at two time points.
The interaction between time and ART history was tested,
and, if statistically significant, remained in the model and
was interpreted rather than the main effects of time and ART
history. Dyslipidemia was determined as TC > 5.2mmol/L,
HDL < 1.1mmol/L, LDL > 3.2mmol/L, and TC/HDL ratio
> 4.5, according to National Cholesterol Education Program,
Adult Treatment Panel III (NCEP ATPIII) guidelines [20].
3. Results and Analysis
3.1. Demographics of Participants. 215 HIV-infected adults
were included in the study at baseline [19], 171 (79%) were
accessed at follow-up, four (2%) had died due to AIDS-
defining illnesses before follow-up, six (3%) transferred from
the clinic, 25 (12%) were lost to follow-up at the clinic for
unknown reasons, and nine (4%) had incomplete follow-up
data. Patients who were eventually declared as lost to follow-
up for unknown reasons were aware that they were required
to attend the study for a second visit and when tracked by
telephone, they declined most likely due to fear of stigma
associated with HIV in many populations of the world [6] or
economic reasons associated with low income in this study
population [19].
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Table 1: Demographics of participants (𝑁 = 171).
Variable ART− (𝑛 = 23) ART+ (𝑛 = 148) Total 𝑃
Age/years
Mean ± SD 36.4 ± 11.2 41.2 ± 10.2 40.5 ± 10.4 0.0417∗
Sex
Male/𝑛 (%) 6 (17.1) 29 (82.9) 35 (20.5) 0.473∗∗
Female/𝑛 (%) 17 (12.5) 119 (87.5) 136 (79.5)
ART use at baseline 23 148 171
NVP/EFV first line — 126 (85.2%)
ZDV/STV first line — 11 (7.4%)
PI-based second line — 11 (7.4%)
Earnings in USD mean ± SD 126.0 ± 143.3 147.8 ± 190.2 144.9 ± 184.4 0.5995∗
BMI mean ± SD 23.5 ± 4.0 24.8 ± 4.9 24.6 ± 4.8 0.2344∗
SBP mean ± SD 125.0 ± 18.8 125.9 ± 18.9 125.8 ± 18.8 0.8154∗
DBP mean ± SD 81.9 ± 18.8 81.7 ± 15.0 81.7 ± 15.5 0.9558∗
Note: level of significance is set atP< 0.05; ∗𝑡-test comparison ofmeans; ∗∗Pearson chi-squared test; SD: standard deviation; BMI: bodymass index; SBP: systolic
blood pressure in mmHg; DBP: diastolic blood pressure in mmHg; ART−: antiretroviral therapy naı¨ve at baseline; ART+: antiretroviral therapy experienced at
baseline; NVP: nevirapine; EFV: efavirenz; ZDV: zidovudine; STV: stavudine; PI: protease inhibitor.
Table 2: Generalised linear model for total cholesterol.
Coefficient Robust standard error 𝑃 95% confidence interval
Lower Upper
Follow-up versus baseline −0.079 0.179 0.658 −0.430 0.271
ART experienced versus ART
na¨ıve 1.436 0.321 <0.001 0.807 2.065
Interaction between time and
ART −0.645 0.200 0.001 −1.036 −0.253
Males versus females 0.094 0.157 0.550 −0.214 0.401
Age (years) 0.028 0.007 <0.001 0.015 0.042
Body mass index at baseline 0.023 0.012 0.062 −0.001 2.028
Constant 1.839
Note: standard error adjusted for 215 clusters in study ID at baseline; ART: antiretroviral therapy, significant 𝑃 < 0.05.
There was no difference in sex, marital status, employ-
ment status, mean earnings, and mean body mass index
(BMI) between the ART naı¨ve and ART experienced patients
at baseline and follow-up (Table 1). However, based on base-
line data, ART experienced patients were generally older than
the ART na¨ıve patients and the majority of the participants
were women [19]. Most of the patients were on first-line ART
comprisingmainly TDF/NVP/3TC andTDF/EFV/3TCwhile
very few (7.4%) were on PI-based second-line regimen, at
baseline (Table 1). 20% of ART+ patients had switched drugs
to either alternative first-line or second-line drugs and 8%
of ART− patients had started ART before second visit. More
ART experienced patients than ART na¨ıve patients, classified
using intent-to-treat, were on treatment for hypertension,
both at baseline [19] and at follow-up nine months later.
By comparing baseline and follow-up data, average TC
andHDL levels were significantly higher in ART experienced
patients than in ART na¨ıve patients while there was no
difference in themean LDL levels. Specifically, mean TC level
of ART experienced patients was on average 1.44mmol/L
higher than for those who were ART na¨ıve, at follow-up
(𝑃 < 0.001), after controlling for sex, age, and baseline BMI
as confounders (Table 2). However, those on ART showed a
highly significant rate of decrease in TC over time compared
with those who were ART na¨ıve (𝑃 = 0.001, Table 2).
At follow-up ART experienced adults, the majority of
whomwere on NVP/EFV first line, had an average HDL level
which was 0.603mmol/L higher than those who were ART
na¨ıve (𝑃 < 0.001) after controlling for baseline diastolic blood
pressure and BMI.ThosewhowereARTnaı¨ve increased their
HDL values over time at a significantly higher rate than those
who were on ART (𝑃 = 0.002).
Also at follow-up patients on ART had LDL level which
was on average 0.146mmol/L higher than those who were
ART na¨ıve, but the difference was not statistically significant
(𝑃 = 0.405) after controlling for baseline systolic blood
pressure. There was no significant interaction between time
and group, but there was an increase in the LDL values in the
ART na¨ıve patients while a decrease in the ART experienced
patients was observed.
Of note, there was an overall decrease in TC/HDL ratio
in both groups over time, which was, however, not different
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Table 3: Comparison of lipid variables of ART na¨ıve and ART experienced patients at baseline and follow-up.
ART history
𝑃
∗ART na¨ıve (𝑛 = 23) ART experienced (𝑛 = 148) Total (𝑁 = 171)
Mean SD Mean SD Mean SD
Baseline TC/mmol/L 3.8 0.8 4.7 1.2 4.6 1.2 <0.001
Baseline HDL/mmol/L 1.0 0.2 1.3 0.4 1.2 0.4 <0.001
Baseline LDL/mmol/L 2.3 1.2 2.7 2.2 2.6 2.1 0.376
Baseline TC/HDL ratio 4.0 1.2 4.0 1.3 4.0 1.3 0.818
ART history
𝑃
∗∗ART na¨ıve (𝑛 = 23) ART experienced (𝑛 = 148) Total (𝑁 = 171)
Mean SD Mean SD Mean SD
Follow-up TC/mmol/L 3.7 0.8 4.0 1.2 4.0 1.1 0.001
Follow-up HDL/mmol/L 1.4 0.4 1.3 0.5 1.3 0.5 0.002
Follow-up LDL/mmol/L 2.6 0.8 2.5 0.99 2.5 0.96 0.118
Follow-up TC/HDL ratio 2.9 1.04 3.5 2.4 3.4 2.3 0.841
Note: SD: standard deviation; level of significance is set at 𝑃 < 0.05; ∗𝑃 from 𝑡-test comparison of means; ∗∗𝑃 from comparisons using generalised linear
models (GLM) time ∗ group estimates. Mean values, for all 171 patients with complete baseline and follow-up data; TC: total cholesterol; LDL: low density
lipoprotein cholesterol; HDL: high density lipoprotein cholesterol; ART: antiretroviral therapy.
Table 4: Comparison of patients with dyslipidemia at baseline and follow-up.
Baseline
ART history





(𝑁 = 171) 𝑃
∗
Elevated TC/𝑛 (%) 1 (4.4%) 55 (37.2%) 56 (32.8%) 0.020
Depressed HDL/𝑛 (%) 17 (73.9%) 77 (52.0%) 94 (55.0%) 0.050
Elevated LDL/𝑛 (%) 5 (21.7%) 34 (23.0%) 39 (22.8%) 0.896
Elevated TC/HDL ratio/𝑛 (%) 6 (26.1%) 35 (23.7%) 41 (24.0%) 0.799
Dyslipidemia/𝑛 (%) 19 (82.6%) 117 (79.1%) 136 (79.5%) 0.694
Nine-month follow-up
ART history





(𝑁 = 171) 𝑃
∗∗
Elevated TC/𝑛 (%) 0 (0%) 23 (15.9%) 23 (13.7%) 0.040
Depressed HDL/𝑛 (%) 9 (39.1%) 69 (46.6%) 78 (45.6%) 0.502
Elevated LDL/𝑛 (%) 2 (34.8%) 30 (20.3%) 38 (22.2%) 0.119
Elevated TC/HDL ratio/𝑛 (%) 2 (88.70%) 17 (11.6%) 19 (11.2%) 0.685
Dyslipidemia/𝑛 (%) 14 (60.9%) 96 (64.9%) 110 (64.3%) 0.710
Note: SD: Standard deviation; level of significance is set at 𝑃 < 0.05; ∗𝑃 from 𝑡-test comparison of means; ∗∗𝑃 fromMcNemar chi square tests for paired data
by time of visit; cutoff values according to NCEP guidelines [20]: elevated TC > 5.2mmol/L, depressed HDL < 1.1mmol/L, elevated LDL > 3.2mmol/L, and
elevated TC/HDL ratio > 4.5.
between the groups. There was no overall difference between
the groups in terms of this outcome (0.841) after adjustment
for age and baseline BMI (Table 3).
Nineteen out of twenty-three (83%) of ARTna¨ıve patients
compared to 79% (𝑛 = 117) of ART experienced patients
(𝑃 = 0.694) had some form of dyslipidemia, at baseline
(Table 4), when classified by absence or presence of any one
of the characteristics of the National Cholesterol Education
Programme Adult Treatment Panel III [20] for TC, LDL,
HDL, and TC/HDL ratio. At follow-up, there was still no
difference in frequency of dyslipidemia when the two groups
were compared (61% against 65%, 𝑃 > 0.05). By comparing
data as matched pairs at baseline and nine months, respec-
tively, there was no significant difference in the proportions
of patients with overall dyslipidemia over nine months for
ART na¨ıve patients, 𝑃 = 0.064, but a significant drop in
the frequency of ART experienced patients with dyslipidemia
(−14.2%, 𝑃 < 0.001) (Table 5).
The prevalence of ART na¨ıve patients with elevated
TC (>6.21mmol/L) showed a slight decrease from one
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Table 5: Changes in frequency of patients with lipid derangements over 9 months.
ART history
ART na¨ıve ART experienced Total 𝑃∗∗
Change in frequency of patients with
elevated TC over nine months −4.4%, 𝑃
∗
= 1.000 −23.5%, 𝑃∗ = 0.281 −16.9%, 𝑃∗ = 0.2288 0.002
Change in frequency of patients with
depressed HDL over 9 months −34.8%, 𝑃
∗ = 1.000 −5.4%, 𝑃∗ < 0.001 −9.3%, 𝑃∗ < 0.001 <0.001
Change in frequency of patients with
elevated LDL over 9 months +13.1%, 𝑃
∗ = 1.000 −2.6%, 𝑃∗ < 0.001 −0.6%, 𝑃∗ < 0.001 0.092
Change in frequency of patients with
elevated TC/HDL ratio over 9 months −17.4%, 𝑃
∗ = 0.688 −12.1%, 𝑃∗ = 1.000 −12.7%, 𝑃∗ = 0.7552 0.143
Change in frequency of patients with
dyslipidemia over 9 months −21.7%, 𝑃
∗ = 0.064 −14.2%, 𝑃∗ < 0.001 −15.2%, 𝑃∗ < 0.001 0.286
Note: SD: standard deviation; level of significance is set at 𝑃 < 0.05; ∗𝑃 fromMcNemar chi square tests for paired data by time of visit; ∗∗𝑃 fromMcNemar chi
square tests for paired data by ART groups; cutoff values according to NCEP guidelines [20]: elevated TC > 5.2mmol/L, depressed HDL < 1.1mmol/L, elevated
LDL > 3.2mmol/L, and elevated TC/HDL ratio > 4.5.
patient to none (Tables 4 and 5), and the proportion
of ART na¨ıve patients with elevated LDL and depressed
HDL (>1.1mmol/L) showed slight decreases which did not
reach statistical significance (Table 5). A similar pattern was
observed for ART+ patients: there were slight decreases in
prevalence of hypercholesterolemia asmeasured byTC, 37.2%
(𝑛 = 55) at baseline versus 15.9% (𝑛 = 23) at follow-up,
𝑃 = 0.281. For ART positive patients, proportion of patients
with depressed HDL and elevated LDL however decreased
significantly over the nine months of follow-up, 𝑃 < 0.0001
(Table 5).The elevated TC/HDL ratios, ameasure of coronary
heart disease risk, showed a decrease over time in both patient
groups (Tables 4 and 5).
4. Discussion
In this HIV population study the serum levels of TC, HDL,
LDL, and calculated TC/HDL ratio in both ART na¨ıve
and ART experienced patients were all within physiological
levels (Table 1). However, many of the patients had some
form of dyslipidemia which implies an increased risk to the
development of coronary heart disease in these patients. At
baseline 83% of ART naı¨ve and 79% of ART experienced
patients had evidence of some form of dyslipidemia and the
high prevalence remained at follow-up nine months later.
Comparing the lipid levels by ART experience showed
a significant difference in serum TC and HDL at baseline
[19] and follow-up (Table 2). Average serum TC and HDL
concentrations were significantly higher in the treated group
at baseline and at follow-up nine months later, while there
was no difference in LDL and TC/HDL ratios between the
two groups (Table 2). Interestingly, TC decreased over time
while HDL increased over time; the ART positive patients
showed more rapid decrease in TC and less rapid increase
in HDL than the ART negative patients. The higher levels
of TC in treated patients are worrying because prolonged
elevated levels of TC (and LDL) increase the development of
atherosclerosis [21].
Our finding is partly consistent with the findings from
the Multicenter AIDS Cohort Study (MACS), a multicenter
prospective cohort study of men in four locations of the
USA. In the MACS study ART initiation was associated
with increases in TC, LDL, non-HDL, and TC/HDL ratio.
The atherogenic lipid profiles occurred shortly after ART
initiation and lent support to the recommendation for base-
line and serial lipid measurements as a standard of care in
the management of HIV treatment [22]. Of note is that at
baseline in our longitudinal study the ART positive patients
had already been on their combined antiretroviral treatment
for mean of 3.5 years [19] while the ART negative patients
were still na¨ıve of antiretroviral treatment, at study baseline.
Although the degree to which serum lipid abnormalities
contribute to the risk of cardiovascular events in HIV-
infected persons is not well established, low HDL level in
an untreated patient is of particular concern as this lipid
abnormality is least amenable to pharmacological therapy.
Encouragingly, in our study the average HDL level increased
in both groups at follow-up, in contrast to reports from the
MACS study, which reported persistence of reduced HDL
level after ART [22]. HDL increased more rapidly in the
ART negative group, in our study, which is surprising as we
expected steeper increase in the ART positive group. Could
HDL increases in ART na¨ıve patients be due to improved
medical care and dietary improvements as the clinic offers
supplements to patients from disadvantaged backgrounds?
This requires further enquiry, bearing in mind that low HDL
levels have previously been associated with longer duration of
HIV infection and higher levels of HIV RNA in circulation
[10] and we have previously reported that the duration of
HIV infection was longer in ART positive patients [19]. It is
however difficult tomake definite conclusions as data on viral
loads and CD4 counts was not available.
When using NCEP guidelines for defining dyslipidemia
there were some interesting findings when comparing the
two patient groups over time. There was a reduction in
prevalence of ART positive patients with depressed HDL
and elevated LDL over the nine months of follow-up, whilst
proportions of ART na¨ıve patients with depressed HDL,
elevated LDL, and elevated TC remained the same. This is
suggestive of decreased prevalence of high risk of coronary
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heart disease in ART positive group due toHDL recovery and
unchanged prevalence of high risk in ART na¨ıve patients over
time, considering that high risk is associated with elevated
TC and low HDL in the general population, over time
[20].
In the study of rural Ugandans with advanced HIV
disease initiating NVP- or EFV-based ART there were infre-
quent elevations in TC, LDL, and TG at baseline and after
24 months of therapy [23]. Increases in HDL levels were
substantial and proportionally greater than increases in TC
or LDL levels. The risk of coronary heart disease and how it
was affected by lipid changes in this rural African population
was not investigated but is expected to be low. Any differences
between these findings and those of the current study could
be due to variations in race/ethnicity, dietary, environmental,
lifestyle factors, and different study designs [24, 25].
In agreement with our study results, an earlier Zimbab-
wean longitudinal study on DART patients over forty-eight
weeks reported low levels of TC, LDL, and TGs at baseline
(time of switch to second-line, after 2.2 years on first-line
ART). After approximately forty-eight weeks of second-
line ART, however, patients were reported to have marked
increases in lipid levels, although TC/HDL ratios remained
unchanged. Higher proportions of patients at follow-up
compared to proportions at baseline had TC and LDL levels
that were greater than normal, whereas lower proportions
of patients had depressed HDL, 𝑃 < 0.001. There was no
difference in proportions of patients with elevated TG and
elevated TC/HDL, 𝑃 > 0.15, suggesting no increase in prev-
alent risk of coronary heart disease over the forty-eight weeks
of follow-up [26]. In a South African longitudinal study TG
and cholesterol levels increased significantly in patients on
stavudine-based first line [27]. Stavudine is however rarely
used in our study clinic so comparison of our results with this
South African study is limited.
5. Conclusion
In conclusion, this present study does confirm that HIV
positive patients, either ART negative or ART positive on
NVP/EFV first-line regimen, show dyslipidemia, although
some changes over time are beneficial. There is still a need
of monitoring the lipid levels routinely in HIV patients who
are either ART naı¨ve or on first-line ART considering that the
Zimbabwean HIV-infected population is getting older and
steadily increasing its risk of coronary heart disease.
6. Limitations
Although the present study has reported relationships
between HIV positivity, ART exposure, and dyslipidemia,
the observational nature of the present study prevents an
establishment of causal relationships between the HIV infec-
tion, the various ART drug regimens, dyslipidemia, and final
coronary heart disease. The study could also not provide
evidence for changes in lipid and coronary heart disease risk
according to type of ART, mainly due to small sample size of
the groups on EFV-based first line and PI-based second line
as small sample sizes lead to imprecise estimations.
7. Recommendations
The study size needs to be larger to be more representative
of the Zimbabwean population, improve power of study, and
reduce type II errors, so as to confirm the findings in this
study. A longer longitudinal study on a larger population that
takes note of both viral loads and CD4 counts, together with
the clinical and biochemical measures, will provide stronger
evidence linking HIV and ART to dyslipidemia and coronary
heart disease. This evidence is urgent in Zimbabwe as the
HIV-infected population not only survives longer, but also
is rapidly aging and hence is more at risk of coronary heart
disease.
Conflict of Interests
The authors declare that there was no conflict of interests in
writing this paper.
Acknowledgments
The authors acknowledge the staff of Department of Medical
Laboratory Sciences, College of Health of Sciences, Univer-
sity of Zimbabwe, and Newlands Clinic staff and patients.
References
[1] “National AIDS Council Preliminary Report,” December 2015,
http://www.nac.org.zw/category/tags/hiv-and-aids-zimbabwe.
[2] Zimbabwe UNAIDS Report, http://www.unaids.org/en/re-
gionscountries/countries/zimbabwe.
[3] S. G. Deeks, S. R. Lewin, and D. V. Havlir, “The end of AIDS:
HIV infection as a chronic disease,” The Lancet, vol. 382, no.
9903, pp. 1525–1533, 2013.
[4] Guidelines for Antiretroviral Therapy for the Prevention and
Treatment of HIV in Zimbabwe, National Medicine and Ther-
apeutics Policy Advisory Committee (NMTPAC), The AIDS
and TBDirectorate, Ministry of Health and Child Care, Harare,
Zimbabwe, 2013.
[5] C. F. Gilks, S. Crowley, R. Ekpini et al., “TheWHOpublic-health
approach to antiretroviral treatment against HIV in resource-
limited settings,” The Lancet, vol. 368, no. 9534, pp. 505–510,
2006.
[6] WHO, Consolidated Guidelines on the Use of Antiretroviral
Drugs for Treating and Preventing HIV Infection. Recommenda-
tions for a Public Health Approach, WHO, 2013.
[7] A. G. Cotter, C. S. Satchell, J. A. O’Halloran, E. R. Feeney, C. A.
Sabin, and P.W.G.Mallon, “High-density lipoprotein levels and
10-year cardiovascular risk in HIV-1-infected patients,” AIDS,
vol. 25, no. 6, pp. 867–869, 2011.
[8] R. H. Haubrich, S. A. Riddler, A. G. DiRienzo et al., “Metabolic
outcomes in a randomized trial of nucleoside, nonnucleoside
and protease inhibitor-sparing regimens for initial HIV treat-
ment,” AIDS, vol. 23, no. 9, pp. 1109–1118, 2009.
[9] M. Galli, A. L. Ridolfo, F. Adorni et al., “Body habitus changes
and metabolic alterations in protease inhibitor-naive HIV-1-
infected patients treated with two nucleoside reverse tran-
scriptase inhibitors,” Journal of Acquired Immune Deficiency
Syndromes, vol. 29, no. 1, pp. 21–31, 2002.
Biochemistry Research International 7
[10] E. R. Feeney and P.W. G.Mallon, “HIV andHAART-associated
dyslipidemia,” The Open Cardiovascular Medicine Journal, vol.
5, pp. 49–63, 2011.
[11] E. Bernal, M. Masia´, S. Padilla, and F. Gutie´rrez, “High-density
lipoprotein cholesterol inHIV-infected patients: evidence for an
association with HIV-1 viral load, antiretroviral therapy status,
and regimen composition,” AIDS Patient Care and STDs, vol.
22, no. 7, pp. 569–575, 2008.
[12] V. Estrada and J. Portilla, “Dyslipidemia related to antiretroviral
therapy,” AIDS Reviews, vol. 13, no. 1, pp. 49–56, 2011.
[13] E. W. P. Yone, A. P. Kengne, G. Ashuntantang, A. F. Betyoumin,
and J. Ngogang, “Dyslipidaemia in HIV-1-infected patients
receiving protease inhibitors after initial treatment with first-
line-based non-nucleoside reverse transcriptase inhibitors: a
cross-sectional study,” BMJ Open, vol. 2, no. 4, Article ID
e001317, 2012.
[14] M. Van Der Valk, J. J. P. Kastelein, R. L. Murphy et al.,
“Nevirapine-containing antiretroviral therapy inHIV-1 infected
patients results in an anti-atherogenic lipid profile,” AIDS, vol.
15, no. 18, pp. 2407–2414, 2001.
[15] E. Fontas, F. Van Leth, C. A. Sabin et al., “Lipid profiles in HIV-
infected patients receiving combination antiretroviral therapy:
are different antiretroviral drugs associated with different lipid
profiles?” The Journal of Infectious Diseases, vol. 189, no. 6, pp.
1056–1074, 2004.
[16] P. J.Weidle, N.Wamai, P. Solberg et al., “Adherence to antiretro-
viral therapy in a home-based AIDS care programme in rural
Uganda,”The Lancet, vol. 368, no. 9547, pp. 1587–1594, 2006.
[17] C. Padmapriyadarsini, S. R. Kumar, N. Terrin et al., “Dyslipi-
demia among HIV-infected patients with tuberculosis taking
once-daily nonnucleoside reverse-transcriptase inhibitor-based
antiretroviral therapy in India,” Clinical Infectious Diseases, vol.
52, no. 4, pp. 540–546, 2011.
[18] M. L. Montes, F. Pulido, C. Barros et al., “Lipid disorders in
antiretroviral-na¨ıve patients treated with lopinavir/ritonavir-
based HAART: frequency, characterization and risk factors,”
Journal of Antimicrobial Chemotherapy, vol. 55, no. 5, pp. 800–
804, 2005.
[19] D. Zhou, V. Kodogo, K. Chokuona, O. Oktedalen, B. Stray-
Pedersen, and E. Gomo, “Dyslipidemia and cardiovascular
disease risk profiles of patients attending an HIV treatment
clinic in Harare, Zimbabwe,” HIV/AIDS—Research and Pallia-
tive Care, vol. 2015, no. 7, pp. 145–155, 2015.
[20] “NECP Expert Panel on detection and early treatment of high
blood cholesterol in adults:Third report of theNational Choles-
terol Education Program (NCEP) expert panel on detection,
evaluation, and treatment of high blood cholesterol in adults
(adult treatment panel III) Final report,” Circulation, vol. 106,
article 3143, 2002.
[21] E. Eren, N. Yilmaz, andO. Aydin, “High density lipoprotein and
it’s dysfunction,” Open Biochemistry Journal, vol. 6, pp. 78–93,
2012.
[22] S. A. Riddler, X. Li, H. Chu et al., “Longitudinal changes in
serum lipids among HIV-infected men on highly active antire-
troviral therapy,”HIV Medicine, vol. 8, no. 5, pp. 280–287, 2007.
[23] K. Buchacz, P. J. Weidle, D. Moore et al., “Changes in lipid
profile over 24 months among adults on first-line highly active
antiretroviral therapy in the home-based AIDS care program
in rural Uganda,” Journal of Acquired Immune Deficiency Syn-
dromes, vol. 47, no. 3, pp. 304–311, 2008.
[24] A. C. Achhra, J. Amin, J. Hoy et al., “Differences in lipid mea-
surements by antiretroviral regimen exposure in cohorts from
Asia and Australia,” AIDS Research and Treatment, vol. 2012,
Article ID 246280, 9 pages, 2012.
[25] E. Cerrato, A. Calcagno, F. D’Ascenzo et al., “Cardiovascular
disease in HIV patients: from bench to bedside and backwards,”
Open Heart, vol. 2, no. 1, Article ID e000174, 2015.
[26] Z. A. R. Gomo, J. G. Hakim, S. A. Walker et al., “Impact of
second-line antiretroviral regimens on lipid profiles in an
African setting: the DART trial sub-study,” AIDS Research and
Therapy, vol. 11, article 32, 2014.
[27] J. A. George, W. D. F. Venter, H. E. Van Deventer, and N. J.
Crowther, “A longitudinal study of the changes in body fat and
metabolic parameters in a South African population of HIV-
positive patients receiving an antiretroviral therapeutic regimen
containing stavudine,” AIDS Research and Human Retroviruses,
vol. 25, no. 8, pp. 771–781, 2009.










Hindawi Publishing Corporation 
http://www.hindawi.com













Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Bioinformatics
Advances in
Marine Biology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Signal Transduction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Evolutionary Biology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Biochemistry 
Research International
Archaea
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Genetics 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in
Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com
Nucleic Acids
Journal of
Volume 2014
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Enzyme 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Microbiology
